- CMC Consulting for Biologics & Gene Therapy
Engineering Confidence from Lab to Launch
Specialized in AAV Gene Therapy
Proven expertise for critical drug development needs, IND through BLA
AAV
A Trusted Partner in Drug Development Proven Solutions for Drug Development Success
At DES Pharma (Dynamic Engineering Solutions), we specialize in product and analytical development. Our services encompass everything from pre-clinical drug development to clinical manufacturing and product commercialization.
FAST, PRECISE & COMPLIANTPersonalized Support for
Pharma Programs
We bring the expertise and focus needed to move your
product forward with speed and confidence.
Program & Process Development
Phase-appropriate process development that ensures product quality, data-driven improvements, and efficient progress from pre-clinical through commercial launch.
AAV Expertise
Quality Control & Analytics
We develop robust analytical methods and leverage scientific expertise to ensure product quality, safety, and efficacy throughout every stage of development.
Gene Therapy Analytics
Supply Chain & Procurement
Customized, end-to-end supply chain strategies to ensure reliable, cost-effective drug product supply from development through commercialization.
Viral Vector Sourcing
Quality Assurance
Comprehensive QA services ensuring compliance and product integrity, including deviation and CAPA management, batch release, and audit support.
Gene Therapy Compliance
Gene Therapy & Viral Vector Expertise Gene Therapy & Viral Vector Expertise
- Specialized AAV Development from Pre-Clinical Through Commercial Launch
At DES Pharma, we bring deep expertise in AAV gene therapy development across all serotypes and manufacturing platforms. Our team has hands-on experience with AAV2, AAV5, AAV8, AAV9, and novel capsid variants, supporting clients through critical development milestones from construct design through commercial manufacturing.
We understand the unique challenges of AAV development: optimizing empty/full capsid ratios, scaling from adherent to suspension cell culture, selecting appropriate purification strategies, and navigating complex regulatory requirements for gene therapies. Whether you’re developing producer cell lines, transitioning from triple-plasmid-to-baculovirus platform support, or preparing for your first IND submission, our consultants provide the technical depth and regulatory insight to accelerate your program.
Our AAV-specific services span the entire development lifecycle, including viral vector characterization, potency assay development, CDMO tech transfer, and BLA preparation support. We help gene therapy companies avoid common pitfalls, reduce manufacturing variability, and build robust processes that meet FDA and EMA expectations.
Serotypes Supported
- AAV2
- AAV5
- AAV8
- AAV9
- Novel Capsids
Capsid Optimization & Producer Cell Lines
Empty/full ratio optimization, adherent-to-suspension transitions, and triple plasmid-to-baculovirus platform support
Potency Assay Development
Vector genome titer, transduction efficiency, and residual DNA testing—IND through BLA
CDMO Tech Transfer & Scale-Up
Vendor selection, tech transfer packages, and manufacturing variability reduction
Regulatory Strategy (IND / BLA)
FDA and EMA-aligned CMC filings, adventitious agent testing, vector shedding protocols
Driving Results & Impact Real Results at Every Stage
End-to-End Development Support
Expertise across the entire drug product lifecycle that helps you meet your milestones.
Efficient, Results-Oriented Approach
Focused on essential experiments and processes to accelerate development.
Robust Quality & Compliance
Ensuring product safety, integrity, and regulatory adherence at every stage.
200+
“Built on Science, Focused on Safety”
Reliable product quality begins with a strategic, system-driven development process. Our team applies a disciplined program design that minimizes risk, streamlines operations, and safeguards patient safety.
Built on Science Consistent Quality, Safer Outcomes
Reliable product quality begins with a strategic, system-driven development process. Our team at DES Pharma applies a disciplined program design that minimizes risk, streamlines operations, and safeguards patient safety.
By embedding quality and compliance at the core of every stage, we deliver results you can trust.
Minimize Risk
Strategic program design eliminates downstream failures
Streamline Operations
Efficient processes from IND through commercialization
Safeguard Patient Safety
Regulatory-aligned quality systems that protect patients
News & Blog ArticlesExplore Recent Insights
Get Started Advance Your Drug Program with Confidence
Start building reliable, high-quality drug development programs today.



